US Steel Deal Seen Closing by Merger Deadline After Trump Pivot
Nippon Steel Corp. and United States Steel Corp. are on pace to finalize their $14.1 billion combination with US President Donald Trump's administration ahead of a deal deadline later this month, capping an 18-month saga to combine the steelmakers into the world's second-largest producer.
Talks on the deal between the companies and the US government are ongoing and expected to reach a conclusion before a June 18 merger agreement deadline, according to people familiar with the matter, speaking on condition of anonymity given that talks are confidential. US Steel and Nippon Steel declined to comment. A Treasury Department spokesperson declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
CBS News
28 minutes ago
- CBS News
Shirley Madigan, wife of former House Speaker Mike Madigan, makes video plea to federal judge before his sentencing
The wife of former Illinois House Speaker Mike Madigan is pleading with a federal judge before his sentencing next week. Shirley Madigan sent a video about her husband, who was convicted on corruption charges, that she hopes will be played in open court. In the video, she explained that she wouldn't know what to do without him around. "I really don't exist without him. I wish I could say that I do, but I don't know what I will do without Michael. I would probably have to find some place to live, and I probably would have to find care," she said. Mike Madigan was convicted of bribery conspiracy, bribery, and wire fraud charges in February, but was acquitted of several other charges after a four-month trial accusing him of running a years-long criminal enterprise to enrich himself and his political allies. He was convicted on 10 counts and acquitted on seven others, while jurors were deadlocked on six other counts against him. The jury also was unable to reach a unanimous verdict on all six charges against his co-defendant, Michael McClain. The verdict was reached after more than 60 hours of deliberations over 11 days. Madigan and McClain faced a 23-count indictment in federal court in Chicago on charges of racketeering conspiracy, bribery, wire fraud, and attempted extortion. They were accused of conspiring with utility companies ComEd and AT&T to provide no-show jobs to Madigan's allies in exchange for the speaker's help on legislation. Prosecutors also accused Madigan of pressuring real estate developers to hire his private law firm, which specializes in property tax appeals. His sentencing is scheduled for June 13.
Bloomberg
30 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
